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Abstract
The cellular immune response to human cytomegalovirus (HCMV) has different components originating
from both the adaptive and innate immune systems. There is a significant global interest in understanding
how the immune system keepsHCMVunder control, in particularwith a view to situations whereHCMV
infection causes severe damage. Such settings include HIV infection, transplantation, and maybe most
importantly perinatal medicine, HCMV being a major cause of sometimes catastrophic birth defects. The
development of an active HCMV vaccine has proven very difficult but some recent successes raise hope
that this might be available in the future. However, adoptive transfer of HCMV-specific T cells has been
successfully used to prevent CMV disease after bone marrow transplantation for many years. In fact, the
CD8 T cell response has been thought to be the most important effector response, with numerous
reports focusing on specific T cell subsets recognizing select peptides in select human leukocyte antigen
(HLA) contexts. However, it is becoming increasingly clear now that other cells, first and foremost CD4
T cells, but also gamma/delta (g/d) T cells and natural killer cells, are critically involved in the cellular
immune response to HCMV. This commentary aims to provide a brief overview of the field.
Introduction
This short commentary will attempt to provide an up-to-
date overview of the contribution of various immune cell
types to the defense against HCMV, a very common
humanDNA virus, which has probably co-evolvedwith its
host since the very beginning of human life [1]. However,
although HCMV is almost a “part” of humankind, not
everybody is infected. On a global scale, HCMV‘s most
damaging impact is related to birth defects, including gross
abnormalities but also sensorineural hearing loss leading
to a learning disability that is sometimes discovered quite
late [2-4]. In addition, HCMV infection is dangerous if
immunity is compromised (for example, in the post-
transplant setting or HIV infection, situations in which it
may cause severe end-organ disease) [5,6].
Over the last decade or so, HCMV has been linked to
premature aging of the immune system (“immunose-
nescence”) as well as premature clinical manifestations
of vascular pathology, particularly in the context of HIV
infection [7-11]. HCMV is noted for sometimes inducing
very large T cell responses but at the same time for
possessing multiple immune evasion mechanisms [12].
The best known of these is probably latency, a “sleep-
like” state with limited protein expression [13].
For a long time, “classic” cytotoxic alpha/beta (a/b) CD8
T cells, recognizing lytic-phase HCMV antigens, were
thought to be the mainstay of cellular anti-HCMV
immunity [14,15]; however, over the last decade or so,
HCMV-specific CD4 T cells have been given increasing
attention as they not only contribute cytotoxic activity in
addition to “classic” helper function but also are a lot
more numerous than previously thought. Of note, CD4
T cells recognizing HCMV proteins expressed during
latency were very recently described. A subpopulation
of these are thought to help HCMV remain sheltered
from the immune response [16].
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A more recent discovery is a subset of HCMV-induced
regulatory T (iTreg) cells that probably develop from
conventional antigen-activated CD4 T cells [17,18].
However, this area is controversial as no widely accepted
general definition of inducible iTregs exists in the
literature, especially not in humans. Among T cells, g/d
T cells have been characterized that initially appeared to
be specific for HCMV but now are understood to
recognize stress antigens expressed (for example, by
HCMV-infected cells) [19,20]. While natural killer (NK)
cells are widely recognized as a first-line innate defense
against HCMV, recent reports provide scope, at least in
theory, for an HCMV-specific major histocompatibility
complex/killer cell immunoglobulin-like receptor
(MHC/KIR)-mediated interaction contributing to silencing
this response [21].
To briefly mention technology, much of the work done in
this area over the last 20 years or so has hugely benefitted
from the advancements in antigen-specific immunology
made in the 1990s. The approaches that have made most
of the difference exploring T cell responses in the HCMV T
cell field were MHC multimer-based approaches [22] and
functional approaches like intracellular cytokine staining
following in vitro stimulation with HCMV antigens (in
particular, protein-spanning peptide pools) or infected
cells [23-27]. The MASIR (measuring antigen-specific
immune responses) series of five conferences between
2005 and 2013 was focused on the measurement of
antigen-specific immune responses and produced a
number of reviews providing a good overview of current
technology in this field [28-30].
Classic effector and helper T cell responses to
human cytomegalovirus infection
Throughout the 1990s, research exploring human HCMV
T cell target antigens focused essentially on two major
protein targets: the pp65 lower matrix phosphoprotein
(UL83, referred to as “pp65” in this review) and the
72 kDa immediate early protein, IE-1 (UL123, referred to
as “IE-1” in this review) [31-34]. The focus of research
during this periodwas clearly on the “cytotoxic”CD8 T cell
response. It is now clear that a broader range of antigens
and cellular functions has to be taken into account. In the
past, responses to epitopes presented by HLA-alleles
common in Western Europe and parts of the United
States (e.g. HLA-A*0201) were prioritized in research
because they are easy to study.
CD4 T cells have not usually been implicated in HCMV-
specific cytotoxicity to the same extent as CD8 T cells,
despite the fact that lysis of HCMV-infected cells by
CD4 T cells was described as early as 1986 [35]. CD4
T cell cytotoxicity was discovered even earlier [36]. Using
modern technology, Appay et al. confirmed in 2002 that
CD28− CD4 T cells (a hallmark of HCMV infection) had
the ability to lyse target cells [37], and in the last 10 years
or so, more and more researchers “rediscovered” CD4
T cell responses to HCMV. Experimental adoptive T cell
transfer in bone marrow transplant patients in the early
1990s had already suggested that CD4 T cells are very
important but their main task was believed to be the
upkeep of CD8 T cell immunity [38]. In 1996, it was
shown that stimulation of peripheral blood mono-
nuclear cells with HCMV viral lysate was able to activate
very large numbers of CD4 T cells based on intracellular
cytokine staining (ICS); however, the full extent of CD4
T cell involvement in the immune response to HCMV
was not clear until a landmark publication in 2005 [27]
changed our perspective entirely, in regard to both CD4
and CD8 T cells. By screening the HCMV proteome using
213 protein-spanning peptide pools [26], it was revealed
that human T cells recognized at least 151 proteins in a
donor population of 33 individuals of mixed MHC
backgrounds. CD4 T cells recognized 125 proteins, CD8
T cells recognized 107 proteins, and 81 proteins were
recognized by both. Of note, until recently, the size of the
HCMV proteome was somewhat underestimated. A recent
publication estimated that the HCMV genome provides
more than 700 protein open reading frames, potentially
coding for many previously untested proteins as well as
smaller proteins overlapping with previously known ones
[39]. Being a very large DNA virus, HCMV adapts to the
host through immune evasion rather than rapid mutation
of target proteins [40]. Nevertheless, the HCMV-specific
T cell response targets mostly proteins that are highly
conserved between different HCMV strains [27]. There is
a tendency for CD4 T cells to predominantly recognize
structural (virion) proteins and for CD8 T cells to
predominantly recognize non-structural proteins; how-
ever, there is huge overlap between the compartments. In
addition to dendritic cell cross-presentation, there areways
in which a HCMV antigen is “packaged” to overcome the
divide of exogenous and endogenous antigen-presenting
pathways. For example, dense bodies are particles full of
HCMV proteins that are secreted by infected cells. They are
internalized by antigen-presenting cells [41,42] essentially
moving endogenous antigens into the exogenous path-
way. Non-infectious enveloped particles secreted by
infected endothelial cells appear to have a similar
function [43].
Preferences for proteins of certain kinetic classes to some
extent relate back to their structural and non-structural
nature (for example, a preference for [non-structural]
immediate early proteins to be recognized by CD8 T cells);
however, CD4 T cells can also recognize these and no strict
divide seems to exist [27].
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T cell responses to HCMV latency-associated proteins were
somewhat “neglected” in the past, mostly because the
identification of latency antigens was delayed compared
with lytic-phase antigens [44]. Not many latency-asso-
ciated antigens are known to date, butMason et al. recently
reported that some of these are recognized by CD4 T cells
[16]. Their work focused on two proteins in particular—
UL138 and LUNA (latency-associated unidentified
nuclear antigen)—both of which are expressed during
lytic infection and latency. CD4 T cells recognizing UL138
and LUNAwere detected in the first instance by interferon-
gamma (IFN-g) enzyme-linked immunosorbent spot
(ELISPOT) assays. In lieu of using complete proteins, the
authors used protein-spanning overlapping peptide pools
for stimulation [26]. More detailed analysis, however,
revealed that, unlike CD4 T cells specific to a lytic-phase
antigen like glycoprotein B, ex-vivo expanded CD4 T cells
specific for LUNA or UL138 also produced IFN-g when
stimulated by latently infected autologous monocytes.
Interestingly, some of these cells also produced cellular
IL-10 (cIL-10) and transforming growth factor-beta
(TGF-b), suggesting that they would subdue T cell
responses rather than accelerate them. These findings
were confirmed for two additional latency-associated
proteins, US28 and vIL-10, which in summary suggests
that latency-associated antigens prime subpopulations
of CD4 T cells with a functional pattern “protective” of
HCMV.
Despite huge efforts, the overall workings of the T cell
response to HCMV are still understood poorly at best. If
there is anything, such as a “formula”, that will allow us
to recognize whether the HCMV-specific T cell response
in a given individual is in control of HCMV or not, it
certainly has not been discovered yet. In humans, one
usually has to work with phenomenological/correlative
results. If such results are good enough to develop
reliable clinical diagnostic tools, they are indeed very
useful. This should, however, not be confused with an
understanding of basic underlying mechanisms. For
example, the monitoring of HCMV-specific CD8 T cells
after bone marrow transplantation with a set of class-I
MHC multimers provided a reasonable surrogate for
“protective” immunity; however, it did not demonstrate
that the T cells being monitored actually had any effect
[45]. In a different study, the adoptive transfer of MHC-
multimer-selected pp65-specific T cells after bone
marrow transplantation provided protection from
HCMV disease, suggesting that pp65-specific T cells can
control HCMV infection [46]. Conversely, however,
patients may develop overt HCMV disease in the face
of even large pp65-specific T cell responses, suggesting
that these cells do not necessarily always control
infection [47].
Immune evasion mechanisms versus success
of the cellular immune response to human
cytomegalovirus
CMV disposes of a large array of strategies to avoid an
efficient immune response and these are thought to be
the reason for its successful survival in both human and
animal populations. Latency appears to be a particularly
important part of the ability of HCMV to hide from the
immune system; however, the number of evasion
mechanisms is such that this fascinating topic has
warranted more reviews than can possibly be referenced
here [12,48-54]. The fact that HCMV-infected people
usually do not have HCMV-related health problems
seems to confirm that the immune response generally
keeps the upper hand, while the success of adoptive T cell
transfer therapy in preventing acute HCMV-related
complications after bone marrow transplantation under-
scores the efficiency of T cells in controlling CMV [55-57].
However, large investigations into different populations
of older people have shown that being HCMV-positive
at an older age may be a considerable disadvantage
[7,58-61]. At this time, though, it is unclear to what extent
this is related to the virus itself or to HCMV-specific
immunity. It may be that very large HCMV-specific T cell
responses, which are found in many (particularly older)
individuals, are neither required nor beneficial but
actually cause damage [62-64]. Some researchers believe
that excessive T cell responses may be the cause of
HCMV-associated premature immune senescence [11],
and there is some evidence to suggest that how the
immune system responds toHCMV determines the degree
of such immune senescence rather than infection per se
[65]. Large T cell expansions are often oligoclonal [66,67]
and their phenotype is CD57+ (a marker associated with
HCMV carrier status) [68] and CD28- [69]. The presence
of a terminally differentiated CD4+CD28- (“CD28 null”)
subpopulation is actually a hallmark of HCMV infection
[70], and as a result, the appearance of such cells in
vascular autoimmune disease (for example, Wegener‘s
granulomatosis) has drawn attention to a possible role of
HCMV in these situations [71,72].
Very large expansions of HCMV-specific T cells are
sometimes referred to as “memory inflation”, a concept
originally derived from inbred mouse models. Many
authors have indeed used inbred mice infected with
murine CMV (MCMV) to model the situation that occurs
in HCMV-infected humans. “Memory inflation” thus
describes the increase of T cell responses to certain
epitopes over time and their long-term maintenance at
high frequencies [73-75]. In mice, unlike in humans
(where the time of infection is usually not known), this
phenomenon can be studied longitudinally. There are a
number of obvious differences between inbred mice and
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humans as there are between MCMV and HCMV, but
essential response mechanisms are still thought to be
very similar. Compared with human models, inbred
mouse models have the advantage that they produce
predictable T cell response patterns that are useful for
studying T cell immunity, albeit in a reductionist way
[73,76]. Other animal models are also being used to
study T cell immunity after CMV infection, including rats
[77,78] and non-human primates [79]. Using rhesus
CMV (RhCMV) as a vector in a novel and highly effective
simian immunodeficiency virus (SIV) vaccine has
exploited the fact that CMVs attract large and persistent
T cell responses [80,81].
Cytomegalovirus-induced regulatory T cells
Recent years have seen an explosion of information on
the critical role of regulatory T cells (Tregs) in the control
of T cell effector responses, peripheral tolerance, and
immune homeostasis. Tregs can develop in the thymus
(natural Tregs, or nTregs) or can be induced in the
periphery by the antigen activation of naïve T cells
(inducible Tregs, or iTregs) in response to a variety of
conditions, as recently reviewed by Bilate et al. [82]. In
particular, iTregs can be generated in response to sub-
immunogenic doses of antigen [83] and chronic
inflammation, as has been observed in several infections
[84-86]. It is believed that the expansion of iTregs in
infection has the beneficial role to limit the magnitude
and duration of inflammatory responses and conse-
quential tissue damage and at the same time drive the
establishment of chronic infection. Tregs appear to
control the activation of effector T cell responses by
competition for growth factors, secretion of soluble
factors, and cell-cell interaction. The expression of the
high-affinity IL-2 receptor CD25 allows Tregs to decrease
the local concentration of IL-2, an essential growth factor
for effector cells. Among other mechanisms, Tregs also
express relatively high levels of cytotoxic T-lymphocyte
antigen 4 (CTLA-4), an extrinsic regulator of T cell
responses [87,88], and through CTLA-4 stimulate den-
dritic cells (DCs) to produce the enzyme indoleamine
2,3-dioxygenase, which degrades the essential amino
acid tryptophan into pro-apoptotic kynurenine [89].
The ectonucleotidase, CD39, equally expressed on
Tregs, catabolises inflammatory ATP to anti-inflamma-
tory adenosine [90,91].
We currently lack reliable phenotypic markers for the
discrimination of iTregs and nTregs. Moreover, the
identification of iTregs is complicated by the existence
of alternative subpopulations that include but are not
limited to IL-10-producing Tr1 and TGF-b-producing Th3
cells [92,93]. Among the expression markers associated
with Tregs, the forkhead transcription factor FoxP3
(forkhead box P3) was once considered a “benchmark”
identifier as it was believed to be essential for Treg
development [94]. However, FoxP3 is also (transiently)
upregulated on activated CD4 T cells and not necessarily
stably expressed in populations of suppressive iTregs
[95-97]. Alternative markers, such as the transcription
factor Helios (Izf2) [98] and the surface protein
neuropilin-1 [99-101], have, likewise, remained unsatis-
factory for the discrimination of nTregs and iTregs.
We have recently identified a population of antigen-
activated iTreg cells by combining canonical Treg markers,
CD25 and CD39, with the activation marker CD134
(OX40) [17,102]. Interestingly, iTregs defined this way
were increased in HCMV-infected older people and
associated with increased resting blood pressure, suggest-
ing a role of HCMV in driving vascular changes in older
life. These findings add to a number of published articles
associating HCMV infection with vascular complications
[9,10]; however, no direct link between the T cell response
to HCMV and blood pressure had previously been made.
Other cellular responses to human
cytomegalovirus infection: g/d T cells
and natural killer cells
g/d T cells are not normally frequent in peripheral blood
but are very frequent in gut epithelium [103]. Among g/d
T cells, the Vd2- population is of particular interest in
HCMV infection because its long-term expansion is almost
like a signature of HCMV infection [20]. Recently, major
inroads into the cognate ligands of this population in the
context of HCMV infection were made [19]. While these
cells are not strictly speaking HCMV-specific, they can
effectively lyse HCMV-infected fibroblasts and endothelial
cells as a result of a cellular stress response that leads to
the upregulation of endothelial protein C receptor (EPCR)
plus co-stimulatory molecules like CD54 (ICAM-1).
Earlier reports suggested that a Vg9- g/d T cell population
including Vg8 Vd1 cells with a “public” Vd1 complemen-
tarity determining region 3 T cell receptor (TCR) sequence
plays a role in utero in congenital HCMV infection;
however, the antigen recognized by these cells has not
been identified yet [104].
NK cells belong to the innate immune response and
are equipped with receptors exhibiting much less
polymorphism than the TCR. They express a range of
inhibitory and activating surface receptors, including
lectin-like receptors and Ig-like receptors (KIRs). The
inhibitory lectin-like receptor CD94/NKG2A/B interacts
with the (non-classic) class Ib MHC molecule HLA-E,
stable expression of which depends on the presentation
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of (classic) class Ia MHC molecule leader sequences.
However, HLA-E can also be upregulated/stabilized by an
HCMV-encoded peptide that is part of the glycoprotein
UL40 sequence, a protein involved in immune evasion
[105,106]. It is interesting that HCMV infection leaves a
stable imprint on the KIR repertoire in infected indivi-
duals involving the activating KIRs, KIR2DS4, KIR2DS2,
and KIR2DS1. This suggests that certain NK cells are
indeed selected by HCMV infection [107]. These
mechanisms are nowhere nearly as specific as TCR/
MHC/peptide interactions; however, there is clearly an
element of specificity and “memory” usually not
associated with innate immunity. NK cell memory is a
fairly recent discovery in a rapidly evolving field [108].
Recently, NK cell specificity was reported from the HIV
field as it was shown that an HIV-1 p24-derived epitope
can be presented byHLA-Cw*0102 andmodulate the NK
cell response via the ligand KIR2DL2 [21]. Similar
mechanisms may be active in HCMV infection, but this
field is only beginning to be explored.
Conclusions and outlook
In summary, we still lack a real understanding of how the
cellular immune response to CMV is actually organized
and functions as a whole to provide protection. Many
inroads have been made into understanding individual
immune response elements (commonly studied aspects
involving target specificity, response size, avidity,
functionality, phenotype, and clonality); however,
the next step needs to be the integration of these
elements into a bigger picture. In order to make a real
difference, we need to understand the correlates of
protection. This would critically improve the manage-
ment of patients and assist an effective CMV vaccine
design.
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